Omlek

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omlek

Property Description
Active Ingredient Omeprazole
Form Delayed-release capsule / tablet
Pharmacological Class Proton Pump Inhibitor (PPI)
Common Use Reduction of gastric acid
Origin Synthetic compound
Status Prescription-only medicine (Rx)

Omlek is the trade name for the medicine whose active ingredient is Omeprazole, a synthetic compound classified as a potent Proton Pump Inhibitor (PPI). Its core purpose is the significant and sustained reduction of gastric acid production in the stomach. Omeprazole is the active therapeutic substance within this single-ingredient product.


What Type of Medicine is Omlek?

Omlek belongs to the Proton Pump Inhibitor (PPI) class, which means it functions as a gastric acid secretion inhibitor. This classification identifies the drug as being chemically related to the substituted benzimidazole family. The mechanism of action is characterized by its ability to achieve acid control compared to older classes of acid-reducing drugs.

Composition, Origin, and Available Forms

The synthetic Omeprazole active ingredient is susceptible to degradation by stomach acid. To circumvent this, Omlek is supplied in specialized drug forms, predominantly as an enteric-coated formulation contained within a delayed-release capsule or delayed-release tablet. This design ensures the medication is released only after it passes into the small intestine, supporting effective bioavailability via oral administration. Additionally, formulations for intravenous (IV) solution are available for clinical use where oral intake is not possible.

General Purpose and Mechanism Summary

The general purpose of Omlek is to achieve a substantial and sustained reduction of gastric acid in the gastric parietal cells. By acting as an antiulcer agent, it helps neutralize the corrosive environment of the stomach. This reduction of acid creates conditions conducive to healing and is the fundamental result of its irreversible inhibition of the acid-secreting proton pump.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Omlek?

Possible Side Effects and Safety Information

The safety profile of Omlek (Omeprazole) is formally categorized by regulatory bodies based on the frequency and the System-Organ Class (SOC) affected. Adverse reactions are grouped across multiple systems, including Gastrointestinal disorders, Nervous system disorders, Hepatobiliary disorders, and Skin and subcutaneous tissue disorders.


Frequency-Classified Adverse Reactions

Common reactions, meaning they are observed in more than 1 in 100 people, typically include headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence. Reactions classified as Uncommon include insomnia, dizziness, and increases in liver enzymes.


Serious Adverse Reactions and Duration-Related Risks

Officially documented serious adverse reactions, though typically classified as Rare or Very Rare, include Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome, and Acute Tubulointerstitial Nephritis (TIN).

Regulatory labeling explicitly notes safety patterns tied to long-term use (generally defined as a year or longer). These patterns include an association with an increased risk of bone fracture, the development of benign fundic gland polyps, and deficiency of Vitamin B12 or hypomagnesaemia.

Safety constraints documented in regulatory sources include the medicine’s potential to mask the symptoms of gastric malignancy and an association with an increased risk of Clostridium difficile-Associated Diarrhea. For special populations, the safety profile in pediatrics is considered similar to adults, although fever and respiratory events were frequently reported in studies of that group.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Omlek (Omeprazole) overdose primarily focuses on the clinical presentation following large ingestions and the mandated response protocols. Reports associated with doses up to 2,400 mg have documented manifestations that are generally transient and without severe clinical consequences.

Documented Overdose Manifestations
Gastrointestinal Effects Nausea, vomiting, diarrhea, abdominal pain
CNS Effects Headache, confusion, dizziness, somnolence (drowsiness)
Systemic Effects Tachycardia (rapid heartbeat), dry mouth, blurred vision, flushing

Required Emergency Actions

In all instances of suspected Omlek overdose, official labeling requires individuals to seek immediate medical attention. This means contacting emergency services or a national Poison Help line for urgent, professional guidance, as the documented effects still warrant immediate clinical assessment.

Management and Treatment

The official regulatory position is that no specific antidote is known for Omeprazole overdose. Consequently, management is strictly symptomatic and supportive treatment. Furthermore, due to the drug’s high level of protein binding, procedures such as hemodialysis are not expected to be effective for increasing drug clearance.

Therapeutic Uses of Omlek

What Omlek treats: main uses and benefits

Omlek is a medication belonging to the class of proton pump inhibitors (PPIs). Its primary function is to reduce the production of gastric acid by inhibiting the enzyme system in the stomach lining responsible for acid secretion.

Primary Indications

This medication is used to manage several conditions related to excessive stomach acid, including:

  • Gastroesophageal Reflux Disease (GERD): It helps alleviate symptoms such as heartburn and acid regurgitation by preventing stomach acid from rising into the esophagus.
  • Gastric and Duodenal Ulcers: It is used in the treatment and prevention of ulcers in the stomach and the upper part of the small intestine.
  • Erosive Esophagitis: It aids in the healing of inflammation and tissue damage in the esophagus caused by prolonged acid exposure.
  • Zollinger-Ellison Syndrome: It is used to manage this rare condition where the stomach produces excessive amounts of acid due to specific tumors.

Benefits of Treatment

The reduction of stomach acid through the use of Omlek provides several clinical benefits focused on recovery and symptom management:

  • Symptom Relief: Significant reduction in the frequency and severity of burning sensations in the chest and throat.
  • Tissue Healing: By creating a less acidic environment, the medication allows the mucosal lining of the esophagus and stomach to repair itself.
  • Complication Prevention: Long-term management helps reduce the risk of more severe complications, such as esophageal strictures or Barrett's esophagus, which can result from chronic acid damage.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Omlek

Official regulatory documents define specific populations who must avoid using Omlek and others who require special caution. Omlek is strictly contraindicated in patients with:

  • Known Hypersensitivity to Omlek, any substituted benzimidazoles (a class of drugs to which Omlek belongs), or any component of the formulation.
  • Concomitant use with products containing Rilpivirine (used for HIV-1 infection) as this is prohibited due to the risk of reduced antiviral effectiveness.

Populations Requiring Special Consideration

Use of Omlek requires careful medical assessment in several restricted populations:

Population Category Eligibility Status (Regulatory Basis)
Severe Hepatic Impairment Not Recommended; dose adjustment or avoidance may be necessary due to altered drug clearance.
Pregnancy and Lactation Use in pregnancy is generally not recommended unless the potential benefit justifies the potential risk. Use during lactation is discouraged due to potential risk to the infant.
Pediatric Patients Use is not established for certain age groups, and specific pediatric dosing or product formulations must be consulted based on official labeling.
Asian Patients Use of Omlek in certain combination products is restricted/advised against unless benefits outweigh risks, according to some regulatory labels.

These official statements delineate the specific constraints and exclusions that structure the drug's approved eligibility profile.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Omlek (Omeprazole) is defined by its ability to inhibit the CYP2C19 enzyme and its effect of raising gastric pH.

Contraindicated and Avoided Combinations

Co-administration with the antiretroviral Rilpivirine is contraindicated due to the potential for a significant reduction in its plasma levels, risking loss of therapeutic effect. Use with the antiplatelet agent Clopidogrel is generally avoided as Omeprazole decreases the exposure of its active metabolite via CYP2C19 inhibition. Concomitant use with the antiretroviral Nelfinavir is similarly restricted.

Impact on Drug Exposure

Omeprazole may prolong the elimination of drugs metabolized by CYP2C19, including Warfarin and Phenytoin, requiring close monitoring for increased exposure. It may also increase serum levels of Tacrolimus and Digoxin. Conversely, the increased gastric pH caused by Omlek reduces the absorption and effectiveness of acid-dependent drugs, such as Atazanavir and Ketoconazole, and necessitates separation from substances like Iron Salts.

Timing and Procedural Constraints

The medicine's use must be temporarily stopped for a period of at least 14 days prior to assessing Chromogranin A (CgA) levels, a diagnostic test, to prevent false results. St. John’s Wort and Rifampin are documented to reduce Omeprazole concentrations and should be avoided. The risk of interaction may be heightened in patients with hepatic impairment.

Mechanism of Action

How Omlek Works: Inhibiting the Acid Pump

Omlek (omeprazole) works by targeting the H^+/ K^+-ATPase enzyme, known as the proton pump, which is the final enzyme in the parietal cells responsible for secreting acid into the stomach. The drug's mechanism of action involves a chemical cascade: Omlek is activated by acid and then forms a strong, irreversible (covalent) bond with the proton pump. This action leads to the inactivation of the acid-secreting proton pump units.

Physiological Effect: Sustained Acid Suppression

This targeted, irreversible blockade leads directly to the drug's core physiological effect: a reduction in the output of hydrochloric acid from the stomach. Because the mechanism involves permanent inactivation, the stomach's acid output remains suppressed until the parietal cells can synthesize new, functional proton pumps. This sustained change in acidity (increase in pH) influences the chemical environment of the upper gastrointestinal tract and supports a chemical environment conducive to the function of the mucosal lining.

Dosage and Administration Information

Administration Guidelines for Omlek

Omlek is administered according to specific procedural steps and dosing rules.

Dosing and Route

The approved route of administration is oral. The standard initial dosage schedule is 15 mg once daily. This medicine may be taken independently of meals, meaning it can be consumed with or without food. Dosage adjustments based on specific conditions, such as severe renal impairment, are defined for the prescriber.

Administration Procedure

Omlek tablets must be swallowed whole with an adequate amount of liquid. The tablets must not be crushed, cut, or chewed, as this can affect the intended drug release. The daily dose should be taken at approximately the same time each day to maintain a consistent schedule.

Handling Missed Doses

If a dose of Omlek is missed, patients should take it as soon as they remember, unless the next scheduled dose is due in less than 12 hours. In that specific circumstance, the missed dose must be skipped entirely, and the regular schedule should be resumed with the next scheduled dose. The dose should not be doubled to make up for a missed one.

Population-Specific Instructions

Omlek is not recommended for use in pediatric patients (those under 18 years of age) due to insufficient data. For geriatric patients (ge 65 years), no specific initial dose reduction is generally required unless pre-existing conditions (e.g., impaired kidney function) necessitate a defined dose reduction.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Omlek

Evidence for Use in Healing Erosive Esophagitis (EE) and Managing GERD Symptoms

Omlek, which contains the active ingredient Omeprazole, research explored its use in relation to the healing of esophageal erosions (Erosive Esophagitis or EE). Research also explored its application in patients experiencing frequent, distressing symptoms of Gastroesophageal Reflux Disease (GERD).

The primary research consists of numerous short-term Randomized Controlled Trials (RCTs). These studies examined outcomes related to inflammatory or irritative states. For EE, studies monitored the frequency of endoscopic healing, while for GERD, research explored short-term symptom changes, focusing on patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies that involved a comparison against other known treatments.

Evidence for Ulcer Healing and H. pylori Eradication

Omlek research explored its application in adult patients with active duodenal ulcers. This research involves RCTs and systematic reviews that examined outcomes related to functional imbalance. Studies monitored the endoscopic healing frequency of the ulcers and the patterns in which symptom reports changed during the observation period.

Additionally, Omlek research explored its application as part of a multi-drug regimen where the eradication of Helicobacter pylori was an outcome studied. The evidence base describes patterns that favor combination therapy with antibiotics, as the comparative evidence is lacking for Omlek monotherapy as a long-term approach for recurrence prevention.

Durability of Effect and Long-Term Follow-up

For indications like Erosive Esophagitis, research examined the long-term patterns for maintaining the healing achieved. Controlled follow-up durations were limited, with most high-quality maintenance trials observing responses over defined time intervals extending up to about one year. Studies that followed patients for much longer durations are typically observational settings evaluating daily-life functioning, and the certainty remains low compared to controlled trials.

Research in Special Populations and Uncertainties

Omlek research examined studies involving pediatric populations (children), including those from 1 to 16 years of age. Data for certain groups remain insufficient, with limited information available in key subgroups such as infants. There is limited information for long-term outcomes regarding the effects of using the medicine for many years continuously. The main research limitations include the lack of long-term, high-power RCTs and the noted variability in patient reports observed in some studies.

Frequently Asked Questions (FAQ)

Common questions about Omlek (FAQ)


Q: How quickly can someone expect Omlek to start working?

Official information indicates that Omlek may begin to provide relief of symptoms within 24 hours of the first dose. However, the full effect on acid suppression may become fully established between one and four days.


Q: What is the longest someone can typically use Omlek for?

The recommended duration of use is defined by the medical condition under treatment. For certain acute conditions, treatment courses are typically limited to 4 to 8 weeks. Maintenance therapy is also described in the official labeling for chronic or long-term conditions.


Q: Can Omlek be taken with supplements or vitamins?

Regulatory information describes that long-term use of Omlek has been associated with effects on the absorption of certain nutrients, such as Vitamin B12. Additionally, certain herbal products, including St. John's Wort, are documented to reduce the concentration of Omlek in the body.


Q: Is there a generic version of Omlek available?

Omlek is the trade name for the active ingredient Omeprazole. This active substance is widely available under its generic name, which is classified as a Proton Pump Inhibitor (PPI).


Q: Can I take Omlek if I have kidney problems?

Official labeling states that while general dose adjustments are not universally specified for all cases of kidney impairment, a defined dose reduction may be required, as outlined in the official prescribing information for severe kidney impairment. This is due to the potential for altered drug clearance.


Q: Does Omlek contain any common allergens like gluten or lactose?

Official product labeling for some formulations of Omlek (Omeprazole) lists inactive ingredients, which may include substances such as lactose monohydrate. Patients are advised to consult the full ingredient list for the specific formulation being used.


Q: How long does Omlek stay in your system?

The physical time the drug remains in the bloodstream (known as half-life) is quite short, usually less than an hour. However, the acid-suppressing pharmacological effect lasts much longer because Omlek works by causing an irreversible blockage of the stomach's acid-producing pumps.


Q: Why is Omlek not recommended for people with kidney disease?

The need for dose adjustment in cases of severe kidney impairment is related to the drug's metabolism. Slower elimination of the drug’s metabolites can lead to a higher systemic exposure level, which necessitates caution and possible dose modification.


Q: Is Omlek available over the counter?

Specific formulations and lower strengths of the active ingredient, Omeprazole, have received regulatory approval for non-prescription, over-the-counter (OTC) use. These are typically indicated for the treatment of frequent heartburn.


Q: Can I stop taking Omlek suddenly?

Official documents and regulatory reviews describe that abrupt discontinuation after long-term use may result in a temporary recurrence of symptoms. This is due to a physiological response called rebound acid hypersecretion.


Q: Are there any common foods or drinks to avoid while using Omlek?

Official information states that the medicine can be taken with or without food. While no specific foods are documented to interact directly with the drug itself, consumption of alcohol or highly acidic foods is commonly known to aggravate underlying acid-related symptoms.


Q: Is it normal to feel tired after starting Omlek?

Post-marketing reports and regulatory documents note that uncommon reactions can include fatigue or malaise. Unusual tiredness is also described as a symptom associated with long-term safety risks, such as Vitamin B12 deficiency or severe adverse reactions.


Q: Is Omlek approved for children?

Official labeling confirms that Omlek (Omeprazole) has approved uses for specific short-term treatments in pediatric patients, including those with symptomatic GERD and erosive esophagitis, as specified by regulatory agencies.


Q: Do I need any specific tests before starting Omlek?

Regulatory documents recommend that the prescribing clinician should assess the patient’s medical status. This includes assessments aimed at excluding the possibility of an underlying stomach malignancy prior to initiating treatment.


Q: Will taking Omlek show up on a drug test?

Omlek (Omeprazole) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means it is not a substance typically screened for in standard drug tests.


Q: Are there any restrictions on driving while using Omlek?

Driving or operating machinery is generally permitted when using Omlek. The official product information notes that caution may be necessary if a user experiences documented side effects such as dizziness or disturbances in vision.


Q: Has Omlek been studied in diverse populations?

Official documents acknowledge that the drug's metabolism can vary across different populations. For instance, the rate of drug clearance may differ in certain Asian patients, indicating that population-specific differences have been studied and noted in regulatory labeling.


Q: Is Omlek addictive?

Omlek (Omeprazole) is not classified as a controlled substance by regulatory authorities, which means it is not considered to have an addictive potential.


Q: Are there known long-term side effects associated with Omlek?

Regulatory labeling notes specific safety patterns associated with use for a year or longer. These documented safety patterns include an association with an increased risk of bone fracture, the development of benign fundic gland polyps, and Vitamin B12 deficiency.


Q: Does Omlek affect fertility?

Rare, post-marketing reports have included effects on reproductive health, such as impotence in men and changes in libido or menstruation in women. These effects are documented in official adverse reaction sections.


Q: Can men and women use Omlek for the same condition?

The regulatory indications for Omlek use are defined by the medical condition, such as duodenal ulcers or GERD. These indications do not typically specify separate treatments or restrictions based on the patient's sex.


Q: What is the risk of having an allergic reaction to Omlek?

Known hypersensitivity to Omlek is a contraindication. While common side effects are usually mild, severe allergic reactions like anaphylaxis and severe cutaneous reactions are officially documented but typically classified as Rare or Very Rare.


Q: Are there any diet changes recommended when taking Omlek?

Regulatory documents do not require specific diet changes, as the medicine can be taken with or without food. While regulatory documents do not specify diet changes, it is common knowledge that certain foods and drinks can aggravate the underlying acid-related symptoms.


Q: What is the expected duration of treatment with Omlek?

The expected duration of treatment is defined by the specific medical condition. Courses can range from short-term use, such as 4 to 8 weeks for certain acute conditions, to long-term maintenance or indefinite treatment for rare chronic conditions.


Q: Is Omlek a controlled substance?

Omlek (Omeprazole) is not classified as a controlled substance by regulatory authorities.


Q: Does Omlek have to be taken with food?

Official administration guidelines explicitly state that the medicine may be taken independently of meals. This means it can be consumed with or without food without affecting its intended function.

How should Omlek be stored and disposed of?

How to Store and Dispose of Omlek?

The storage and disposal instructions for Omlek (Omeprazole Delayed-Release Capsules) are based strictly on official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store below 30 C or not above 25 C (varies by label).
Protection Must be protected from light and moisture; store in a dry place.
Packaging Keep in the original container and ensure the cap is tightly closed.
Child Safety Must be stored out of the sight and reach of children and pets.

Disposal Instructions

Any unused or expired Omlek and related waste material must be disposed of in accordance with local requirements for pharmaceutical products. Disposal should utilize authorized drug take-back or collection programs and should not generally be conducted via household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omlek found in:

A-Z Index: